Results 91 to 100 of about 33,667 (245)

Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background The transition through menopause is accompanied by a series of adverse metabolic changes which are associated with an increased risk of cardiometabolic disease, a major cause of mortality in women after midlife. Whilst the indication for menopausal hormone replacement therapy (HRT) is the control of menopausal symptoms ...
Jiawen Dong, Sarah Hillman, Sharon Dixon, Anupa Shah, Radha Venkatakrishnan, Jeremy W. Tomlinson   +5 more
wiley   +1 more source

Indications and Efficacy of Progestogen‐Monotherapy as Menopause Hormone Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and other manifestations of menopause; however, its use is limited in women with contraindications to oestrogen. Progestogen monotherapy, though historically underutilized, represents a viable alternative in this population. This narrative review
Chloe Thomas, Olivia Carere, Lauren Clarfield, Michelle Jacobson   +3 more
wiley   +1 more source

Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia

, 2014
Rehab Nabil Shamma, Mona Hassan AburahmaDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, EgyptAbstract: Spironolactone (SL) is a US Food and Drug Administration-approved drug for the treatment of ...
Shamma RN, Aburahma MH
core  

The effect of spironolactone on diastolic function in haemodialysis patients

, 2021
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent in patients on maintenance haemodialysis (HD) and lacks effective treatment. We investigated the effect of spironolactone on cardiac structure and function with a specific focus ...
Malzahn, U., Wanner, C., Hauser, T., Nauck, M., Hammer, F., Dörr, M., Krane, V., Dornberger, V., Grebe, S. J., Störk, S., Liu, D., Friedrich, N.   +11 more
core   +1 more source

Muscle Strength and Power Changes With Gender‐Affirming Hormone Therapy

Andrology, EarlyView.
ABSTRACT Background Androgen receptors are highly expressed in upper body muscles, but changes in maximal muscle strength and power in major upper body muscles have not been investigated during gender‐affirming hormone therapy (GAHT). Objective To assess prospective changes in maximal muscle strength and muscle power from before and after 1 year of ...
Mathilde Kamp Nørlund, Jakob Lindberg Nielsen, Marianne Skovsager Andersen, Rikke Hjortebjerg, Laust Frisenberg Buhl, Anne Pernille Hermann, Camilla Viola Buskbjerg Palm, Tine Taulbjerg Kristensen, Jan Frystyk, Per Aagaard, Jonas Mathiesen, Dorte Glintborg, Louise Lehmann Christensen   +12 more
wiley   +1 more source

Feminizing Therapy in People With Klinefelter Syndrome and Gender Incongruence: Considerations for Treatment Without Testosterone Blockers

Andrology, EarlyView.
ABSTRACT Background Klinefelter syndrome (KS; 47, XXY) usually involves male sex development and gender identity. Small studies suggest gender incongruence may be more common in KS, but feminizing gender‑affirming hormone therapy in this group has been scarcely reported.
Maaike Kroon, Tamira Klaziene Klooker, Sabine Elisabeth Hannema, Martin Den Heijer   +3 more
wiley   +1 more source

Spironolactone improves Angiotensin-induced vascular changes and oxidative stress

, 2002
Angiotensin II plays an important role in vascular remodeling. We investigated the role of aldosterone, which is stimulated by angiotensin II, as a mediator of angiotensin II–induced vascular structural and functional alterations.
Touyz, R.M., Amiri, F., Viel, E., Ernesto L. Schiffrin, Agostino Virdis, Schriffin, E.L., TOUYZ RM, NEVES MF, Rhian M. Touyz, SCHIFFRIN E.L., VIRDIS, AGOSTINO, Farhad Amiri, Virdis, A., Neves, M.F., VIEL E, Mario Fritsch Neves, Emilie Viel, AMIRI F   +17 more
core   +1 more source

Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients. [PDF]

, 2017
Hypokalemia is common in peritoneal dialysis (PD) patients and is associated with increased cardiovascular and all-cause mortality. The management approach for such patients routinely includes spironolactone at our centre.
Swapnil Hiremath, Marcel Ruzicka, Brendan B McCormick, Amit Langote   +3 more
core   +1 more source

Prospective Short‐ and Long‐Term Changes in Cardiometabolic Risk Markers Following Gender‐Affirming Hormone Therapy

Andrology, EarlyView.
ABSTRACT Introduction Gender‐affirming hormone therapy (GAHT) may be associated with increased cardiometabolic disease (CMD) risk. Prospective CMD risk screening is recommended, but long‐term data are needed regarding changes in CMD markers. Objectives To evaluate prospective changes in CMD risk markers during GAHT.
Louise Lehmann Christensen, Camilla Viola Palm, Marianne S. Andersen, Guy T'Sjoen, Jan Frystyk, Tine Taulbjerg Kristensen, Rikke Hjortebjerg, Dorte Glintborg   +7 more
wiley   +1 more source

Data for spironolactone toxicosis

Ong et al. Spironolactone toxicosis in cats and dogs: a retrospective study highlighting dermatologists’ role in patient education; Table
Ong, Michael
core   +1 more source